Hefei Lifeon Pharmaceutical Future Growth
Future criteria checks 4/6
Hefei Lifeon Pharmaceutical is forecast to grow earnings and revenue by 29.9% and 14.6% per annum respectively while EPS is expected to grow by 29.9% per annum.
Key information
29.9%
Earnings growth rate
29.9%
EPS growth rate
Pharmaceuticals earnings growth | 18.5% |
Revenue growth rate | 14.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 02 Nov 2023 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 1,822 | 336 | N/A | 350 | 2 |
12/31/2024 | 1,519 | 285 | N/A | 337 | 2 |
3/31/2024 | 1,423 | 191 | 12 | 198 | N/A |
12/31/2023 | 1,901 | 227 | 6 | 204 | N/A |
9/30/2023 | 2,210 | 210 | -117 | 138 | N/A |
6/30/2023 | 2,618 | 243 | -144 | 129 | N/A |
3/31/2023 | 2,763 | 229 | -48 | 208 | N/A |
1/1/2023 | 2,579 | 209 | -46 | 201 | N/A |
9/30/2022 | 2,503 | 217 | -2 | 167 | N/A |
6/30/2022 | 2,429 | 187 | 64 | 249 | N/A |
3/31/2022 | 2,353 | 178 | -48 | 165 | N/A |
12/31/2021 | 2,273 | 172 | -28 | 159 | N/A |
9/30/2021 | 2,183 | 161 | -41 | 134 | N/A |
6/30/2021 | 2,076 | 153 | -7 | 115 | N/A |
3/31/2021 | 1,991 | 148 | 91 | 163 | N/A |
12/31/2020 | 1,894 | 135 | 116 | 172 | N/A |
9/30/2020 | 1,809 | 127 | 161 | 205 | N/A |
6/30/2020 | 1,758 | 120 | 158 | 201 | N/A |
3/31/2020 | 1,711 | 109 | 100 | 143 | N/A |
12/31/2019 | 1,650 | 105 | 105 | 149 | N/A |
12/31/2018 | 1,425 | 92 | 35 | 64 | N/A |
12/31/2017 | 1,167 | 77 | N/A | 11 | N/A |
12/31/2016 | 1,028 | 67 | N/A | 59 | N/A |
12/31/2014 | 962 | 54 | N/A | 92 | N/A |
12/31/2013 | 878 | 47 | N/A | 36 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 003020's forecast earnings growth (29.9% per year) is above the savings rate (2.9%).
Earnings vs Market: 003020's earnings (29.9% per year) are forecast to grow faster than the CN market (24.1% per year).
High Growth Earnings: 003020's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 003020's revenue (14.6% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 003020's revenue (14.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 003020's Return on Equity is forecast to be high in 3 years time